Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Denosumab |
Synonyms | |
Therapy Description |
Xgeva (denosumab) is an antibody that binds to RANKL protein, inhibiting osteoclast activity and is FDA approved for use in patients with giant cell tumor of the bone (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Denosumab | Xgeva | AMG162|AMG-162|AMG 162|Prolia | Xgeva (denosumab) is an antibody that binds to RANKL protein, inhibiting osteoclast activity and is FDA approved for use in patients with giant cell tumor of the bone (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02900469 | Phase 0 | Denosumab | Safety Study of Denosumab to Treat Breast Cancer | Completed | USA | 0 |
NCT02833610 | Phase II | Denosumab | A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency | Unknown status | USA | 0 |
NCT01545648 | Phase II | Denosumab | Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer | Terminated | USA | 0 |
NCT00680992 | Phase II | Denosumab | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | Completed | USA | SWE | POL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 0 |
NCT03070002 | Phase II | Denosumab | Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells | Terminated | USA | 0 |
NCT01952054 | Phase II | Denosumab | Denosumab for Breast Cancer With Bone Mets | Terminated | USA | 0 |
NCT03839459 | Phase II | Denosumab | Denosumab for Smoldering Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT03605199 | Phase II | Denosumab | Denosumab in Subjects With Giant Cell Rich Tumors of Bone | Unknown status | NLD | ITA | FRA | 0 |
NCT01345019 | Phase III | Denosumab Zoledronic acid | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma | Completed | USA | TUR | SVK | POL | NZL | LTU | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BGR | AUT | AUS | 9 |
NCT02470091 | Phase II | Denosumab | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma | Completed | USA | CAN | 1 |
NCT03301857 | Phase III | Denosumab | Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 | Completed | USA | SWE | POL | ITA | GBR | FRA | ESP | AUS | 0 |